Zhongguancun announced that its subsidiary, Beijing Huasulidocaine Decaine Cream, has received the “Drug Clinical Trial Approval Notice” from the State Drug Administration. The name of the drug is lidocaine tinocaine cream. The specifications are 15g: lidocaine 1,050 mg and tetracaine 1,050 mg; 30 g: lidocaine 2,100 mg and tetracaine 2,100 mg. The approval concluded that it was agreed to carry out clinical trials for local anesthesia for adult skin before skin surgery, and to carry out equivalent clinical trials using reference preparations as controls. Clinical trials aimed at investigating PK characteristics are no longer required.

Zhongguancun announced that its subsidiary, Beijing Huasulidocaine Decaine Cream, has received the “Drug Clinical Trial Approval Notice” from the State Drug Administration. The name of the drug is lidocaine tinocaine cream. The specifications are 15g: lidocaine 1,050 mg and tetracaine 1,050 mg; 30 g: lidocaine 2,100 mg and tetracaine 2,100 mg. The approval concluded that it was agreed to carry out clinical trials for local anesthesia for adult skin before skin surgery, and to carry out equivalent clinical trials using reference preparations as controls. Clinical trials aimed at investigating PK characteristics are no longer required.